A personal care composition comprising: a) from 0.0003 to 10% by weight of a substituted or unsubstituted 2-pyridinol N-oxide material, wherein said substituted or unsubstituted 2-pyridinol-N-oxide material comprises 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone monoethanolamine salt; b) from 0.005 to 15% by weight of at least one chelant, wherein the at least one chelant comprises iron chelators; wherein the combination of the chelant and the substituted or unsubstituted 2-pyridinol N-oxide material increases the antibacterial efficiency of the substituted or unsubstituted 2-pyridinol N-oxide material at least 20%, wherein the iron chelators comprise diethylenetriaminepentaacetic acid (DTPA) and wherein the weight ratio of diethylenetriaminepentaacetic acid (DTPA) to 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone monoethanolamine salt is within the range from 20 to 160; or wherein the iron chelators comprise Diethylenetriaminepentakis (methylenephosphonic acid) (DTPMP) and wherein the weight ratio of Diethylenetriaminepentakis (methylenephosphonic acid) (DTPMP) to 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone monoethanolamine salt is within the range from 2.5 to 80; and c) from 40% to 95% by weight of an aqueous carrier or from 20% to 95% by weight of at least one surfactant. a) from 0.0003 to 10% by weight of a substituted or unsubstituted 2-pyridinol N-oxide material, wherein said substituted or unsubstituted 2-pyridinol-N-oxide material comprises 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone monoethanolamine salt; b) from 0.005 to 15% by weight of at least one chelant, wherein the at least one chelant comprises iron chelators; wherein the combination of the chelant and the substituted or unsubstituted 2-pyridinol N-oxide material increases the antibacterial efficiency of the substituted or unsubstituted 2-pyridinol N-oxide material at least 20%, wherein the iron chelators comprise diethylenetriaminepentaacetic acid (DTPA) and wherein the weight ratio of diethylenetriaminepentaacetic acid (DTPA) to 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone monoethanolamine salt is within the range from 20 to 160; or wherein the iron chelators comprise Diethylenetriaminepentakis (methylenephosphonic acid) (DTPMP) and wherein the weight ratio of Diethylenetriaminepentakis (methylenephosphonic acid) (DTPMP) to 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone monoethanolamine salt is within the range from 2.5 to 80; and wherein the combination of the chelant and the substituted or unsubstituted 2-pyridinol N-oxide material increases the antibacterial efficiency of the substituted or unsubstituted 2-pyridinol N-oxide material at least 20%, wherein the iron chelators comprise diethylenetriaminepentaacetic acid (DTPA) and wherein the weight ratio of diethylenetriaminepentaacetic acid (DTPA) to 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone monoethanolamine salt is within the range from 20 to 160; or wherein the iron chelators comprise Diethylenetriaminepentakis (methylenephosphonic acid) (DTPMP) and wherein the weight ratio of Diethylenetriaminepentakis (methylenephosphonic acid) (DTPMP) to 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone monoethanolamine salt is within the range from 2.5 to 80; and c) from 40% to 95% by weight of an aqueous carrier or from 20% to 95% by weight of at least one surfactant. <EOS>